In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

AstraZeneca and Viking Therapeutics both presented encouraging data on their obesity pills. Meanwhile, here’s how Americans ...

Obesity caused by a lifestyle of moving less and eating more is a prime factor contributing to Type 2 diabetes. Is the answer ...

The pharmaceutical company Viking has recently become one of the most volatile stocks on Wall Street due to the announcement ...

The U.K.-based company released the data at Obesity Week, an event organized by the Obesity ... after investors were underwhelmed by early data from a trial of a weight-loss pill.

AstraZeneca’s new obesity pill, licensed from China’s Eccogene last year, has shown initial promise in early-stage trials.

Cellular's schizophrenia drug meeting trial goals, Britain's new mpox variant detection, proposed UK smoking bans, challenges in weight-loss medication access, CVS Health's strategy adaptation, South ...

While expected and seen as largely incremental, Jefferies analyst Peter Welford in a Tuesday note to investors said the detailed data for three early-stage assets support moving them into Phase IIb ...

The obesity treatment study also produced effects ... Capsules containing screened donor feces are ingested as a pill that dissolves in the gut, introducing viruses and a variety of beneficial ...